Business Context and Reporting Period
This Form 8-K is a current report filed by ReShape Lifesciences Inc. (not Vyome Holdings, Inc.) on May 15, 2024. The filing serves to announce the company's financial results for the three months ended March 31, 2024. The registrant is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol RSLS.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document states that the detailed financial results are contained in a press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the text of this summary.
Material Changes
No material changes versus the prior comparable period are detailed in the provided text. The filing acts solely as a notification that the Q1 2024 results have been issued.
Guidance, Outlook, and Risks
The filing includes a standard legal disclaimer stating that the information furnished pursuant to Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings. No specific guidance, outlook, management commentary, or risk factors are detailed in the text of this 8-K.
Investor Verification Checklist
- Verify the specific revenue, net loss, and cash burn figures in the Exhibit 99.1 Press Release referenced in this filing.
- Confirm the company name is ReShape Lifesciences Inc. (RSLS), as the input metadata incorrectly listed "Vyome Holdings, Inc."
- Review the full press release for any updated guidance or operational milestones for the fiscal year 2024.
- Check the company's liquidity position and cash runway as disclosed in the referenced exhibit.